Lupin acquires Russian drug firm Biocom
Lupin, India's fifth largest drug maker, has entered the Russian market by acquiring 100% stake in Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount. "Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets," said Vinita Gupta, CEO at Lupin.The acquisition marks Mumbai-based firm's entry into the...
Login or Register to read the full article
Lupin, India's fifth largest drug maker, has entered the Russian market by acquiring 100% stake in Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount. "Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets," said Vinita Gupta, CEO at Lupin.
The acquisition marks Mumbai-based firm's entry into the Russian pharmaceutical market which recorded RUB 765 billion in sales.
The acquisition marks Mumbai-based firm's entry into the Russian pharmaceutical market which recorded RUB 765 billion in sales.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd